Artelo Biosciences announces private placement to initiate Solana treasury

Artelo entered into a securities purchase agreement for an at-the market PIPE for the purchase and sale of securities at a price of $10.45, consisting of: 906,687 shares of common stock; three-year warrants to purchase 906,687 shares of common stock at an exercise price of $10.20 per share; and three-year warrants to purchase 906,687 shares of common stock at an exercise price of $50.00 per share, for expected aggregate gross proceeds of approximately $9.475M. This brings aggregate proceeds from private placements priced at-the-market since June 2025 to $10.9M. The Company intends to use the proceeds to launch its Solana (SOL)-centric digital asset treasury strategy, as well as to support Artelo’s ongoing business. Artelo’s treasury initiative marks a pivotal step in its long-term growth strategy, as it becomes the first publicly traded pharmaceutical company to adopt SOL-Solana’s native cryptocurrency-as a reserve asset. This move signals Artelo’s commitment to forward-thinking financial management and positions the Company at the intersection of biotechnology innovation and decentralized finance. By integrating SOL into its balance sheet, Artelo diversifies its treasury while gaining exposure to a next-generation monetary network that complements traditional cash management. Bartosz Lipinski is the lead investor for the launch of Artelo’s SOL treasury strategy and will serve as a technical advisor and a partner through his company CUBE. Artelo’s Board has also approved the expansion of the Company’s SOL treasury strategy, based on staged investments over time, while keeping adequate working capital for the continued development and commercialization of its proprietary therapeutics. The closing of the PIPE is expected to occur on or about August 5, 2025, subject to the satisfaction of customary closing conditions. R. F. Lafferty & Co., Inc. acted as an advisor in connection with the PIPE.